Transforming life for people living with Parkinson’s and other CNS disorders
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam
Gothenburg, Sweden, March 22, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced the receipt of written minutes from a recent End-of-Phase 2 meeting for mesdopetam with the US Food and Drug Administration, FDA. The minutes confirm the previously communicated positive verbal feedback from the meeting. Based on this successful outcome, IRLAB will now move forward with the preparations of the Phase III program.
Read More >Watch IRLAB’s
Capital Markets Day 2023!
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Fireside chat with Viktor Siewertz, CFO, at ABGSC
Viktor Siewertz, CFO, participated in the ABGSC fireside chat, moderated by Alexander Krämer, analyst at ABGSC, The event was recorded on March 5 and published on March 7, 2024.
Read More >